Department of Pediatrics, Taipei Veterans General Hospital, Taipei, Taiwan.
Institute of Emergency and Critical Care Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Ann Med. 2023 Dec;55(1):2230871. doi: 10.1080/07853890.2023.2230871.
Liver transplant recipients have an increased risk of osteoporosis and fractures. The aim of this study was to identify risk factors for fractures after liver transplant in a Taiwanese population.
We identified newly diagnosed liver transplant recipients from the National Health Insurance Research Database in Taiwan between 2003 and 2015. Risk factors of post-transplant fractures were analyzed using a Cox proportional hazards model.
A total of 4821 patients underwent liver transplantation, of whom 419 (8.7%) had post-transplant fractures. Independent predictors of post-transplant fractures were age ≥65 years at transplantation (hazard ratio (HR): 1.566; 95% confidence interval (CI) 1.122-2.186), female sex (HR: 1.648; 95% CI 1.319-2.057), fractures within 1 year prior to transplant (HR: 3.664; 95% CI 2.503-5.364), hepatitis C carriers (HR: 1.594; 95% CI 1.289-1.970), alcoholism (HR: 1.557; 95% CI 1.087-2.230) and daily prednisolone dose >1.61-3.78 mg/day (HR: 1.354; 95% CI 1.005-1.824), >3.78-9.18 mg (HR: 4.182; 95% CI 3.155-5.544) and >9.18 mg (HR: 13.334; 95% CI 9.506-18.703). Post-transplant fractures were inversely correlated with tacrolimus (HR: 0.617; 95% CI 0.417-0.913) and sirolimus/everolimus (HR: 0.504; 95% CI 0.391-0.650) treatment.
The liver transplant recipients, and especially those who were aged ≥65 years, female, hepatitis C carriers, had a history of fractures within 1 year prior to transplant, alcoholism, and higher daily prednisolone dose were associated with an increased risk of post-transplant fractures. Conversely, the use of tacrolimus and sirolimus/everolimus was associated with a decreased risk of fractures.
肝移植受者骨质疏松症和骨折的风险增加。本研究的目的是在台湾人群中确定肝移植后骨折的危险因素。
我们从台湾 2003 年至 2015 年的全民健康保险研究数据库中确定了新诊断的肝移植受者。使用 Cox 比例风险模型分析移植后骨折的危险因素。
共有 4821 名患者接受了肝移植,其中 419 名(8.7%)发生了移植后骨折。移植后骨折的独立预测因素为:移植时年龄≥65 岁(风险比(HR):1.566;95%置信区间(CI):1.122-2.186)、女性(HR:1.648;95%CI:1.319-2.057)、移植前 1 年内有骨折史(HR:3.664;95%CI:2.503-5.364)、丙型肝炎携带者(HR:1.594;95%CI:1.289-1.970)、酗酒(HR:1.557;95%CI:1.087-2.230)和每日泼尼松剂量>1.61-3.78mg/d(HR:1.354;95%CI:1.005-1.824)、>3.78-9.18mg(HR:4.182;95%CI:3.155-5.544)和>9.18mg(HR:13.334;95%CI:9.506-18.703)。移植后骨折与他克莫司(HR:0.617;95%CI:0.417-0.913)和西罗莫司/依维莫司(HR:0.504;95%CI:0.391-0.650)治疗呈负相关。
肝移植受者,尤其是年龄≥65 岁、女性、丙型肝炎携带者、移植前 1 年内有骨折史、酗酒、每日泼尼松剂量较高者,发生移植后骨折的风险增加。相反,使用他克莫司和西罗莫司/依维莫司与骨折风险降低相关。